Background: Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects. Objectives: To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI. Methods: This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed. Results: Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment. Conclusions: CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.
17 September 2026 in Journal of Cosmetic Dermatology
Background: Botulinum toxin type A (BTX‐A) is the cornerstone for treating dynamic wrinkles; however, it requires reinjection every 3–4 months. Adjunctive topical creams that mimic the effect of BTX‐A and enhance its action may prolong treatment intervals. Objectives: To evaluate the efficacy of a novel formulation containing Subderma‐Complex (arginine, niacinamide, and over‐the‐counter neuromodulating peptides, including: Munapsys, X50 Myocept, Syn‐Ake, and Argireline) in extending the duration of BTX‐A's effect. Methods & Materials: Subjects with moderate‐to‐severe facial wrinkles and a history of regular BTX‐A use applied the Subderma‐Complex serum and creams daily following BTX‐A injection. Reinjection was triggered by the reappearance of the first wrinkle. Outcomes were measured across five visits using the Investigator's Global Assessment, Subject Self‐Assessment, and instrumental analysis (VisioFace Lite). Results: Data from 15 participants were analyzed. The mean reinjection interval increased by 65.2%, from 13.5 ± 1.9 weeks at baseline to 22.3 ± 3.6 weeks following topical treatment ( p < 0.001). Both investigator and patient assessments showed significant reductions in wrinkle severity and improvements in skin quality ( p < 0.001). However, the small sample size and lack of a control group limit the generalizability of the findings. Conclusions: Daily application of a Subderma‐Complex formulation was well‐tolerated and significantly prolonged BTX‐A efficacy, potentially reducing reinjection frequency.